PubmedID,Title,Publication Date,Non-academic Author(s),Company Affiliation(s),Corresponding Author Email
40746944,Association of Blood Donor-derived Cell-free DNA Levels With Banff Scores and Histopathological Lesions in Kidney Allograft Biopsies: Results From an Observational Study.,2025,Beck; Bornemann-Kolatzki; Schütz,"Chronix Biomedical GmbH, Göttingen, Germany.; Chronix Biomedical GmbH, Göttingen, Germany.; Chronix Biomedical GmbH, Göttingen, Germany.",N/A
40746940,Dose escalation study of the HLA-A2-WT1 CD3 bispecific antibody RO7283420 in relapsed/refractory acute myeloid leukemia.,2025,Yee; Hinton,"Cancer Clinical Research Unit, Princess Margaret Cancer Centre, Toronto, ON, Canada.; Product Development Safety, F. Hoffmann-La Roche Ltd, Basel, Switzerland.",N/A
40746868,Oral MIB-626 (β Nicotinamide Mononucleotide) Safely Raises Blood Nicotinamide Adenine Dinucleotide Levels in Hospitalized Patients With COVID-19 and Acute Kidney Injury: A Randomized Controlled Trial.,2025,Lavu; Karmi; Livingston,Metro International Biotech Worcester Massachusetts USA.; Metro International Biotech Worcester Massachusetts USA.; Metro International Biotech Worcester Massachusetts USA.,N/A
40745250,Epidemiology of Thrombotic Thrombocytopenia Syndrome 2011 to 2022: English Sentinel Network Cohort Studies.,2025,Lee,"BPM Evidence Statistics, BioPharmaceuticals Business Unit, AstraZeneca, Cambridge, UK.",simon.delusignan@phc.ox.ac.uk.
40745101,[Update of the ESC atrial fibrillation guidelines : From the DGK commission for clinical cardiovascular medicine].,2025,Perings,"Medizinische Klinik I, KLW St. Paulus GmbH, Lünen, Deutschland.",r.schnabel@uke.de.
40744695,Evaluation of Mitochondrial Complex 1 Density with [18F]BCPP-EF in a Murine Model and Individuals with Friedreich Ataxia.,2025,Loudon,"Peter Loudon Consulting Ltd., Cambridge, United Kingdom.",laigao.chen@pfizer.com.
40742659,Preferences for Injectable Lipid-Lowering Therapies in Japanese Patients with Atherosclerotic Cardiovascular Disease: Findings from a Japanese Cross-sectional Study.,2025,Toda; Iekushi; Takahashi,"Medical Affairs Division, General Medicines Medical, Novartis Pharma K.K., 23-1, Toranomon 1-chome, Minato-ku, Tokyo, 105-6333, Japan. mitsutoshi.toda@novartis.com.; Medical Affairs Division, General Medicines Medical, Novartis Pharma K.K., 23-1, Toranomon 1-chome, Minato-ku, Tokyo, 105-6333, Japan.; Medical Affairs Division, General Medicines Medical, Novartis Pharma K.K., 23-1, Toranomon 1-chome, Minato-ku, Tokyo, 105-6333, Japan.",mitsutoshi.toda@novartis.com.
